EA034616B1 - СТАБИЛЬНЫЙ СОСТАВ В ВИДЕ РАСТВОРА АНТИТЕЛА HUM13B8-b К IL-23p19 И СПОСОБ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ, ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ ИЛИ ПРОЛИФЕРАТИВНОГО НАРУШЕНИЯ - Google Patents

СТАБИЛЬНЫЙ СОСТАВ В ВИДЕ РАСТВОРА АНТИТЕЛА HUM13B8-b К IL-23p19 И СПОСОБ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ, ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ ИЛИ ПРОЛИФЕРАТИВНОГО НАРУШЕНИЯ Download PDF

Info

Publication number
EA034616B1
EA034616B1 EA201591133A EA201591133A EA034616B1 EA 034616 B1 EA034616 B1 EA 034616B1 EA 201591133 A EA201591133 A EA 201591133A EA 201591133 A EA201591133 A EA 201591133A EA 034616 B1 EA034616 B1 EA 034616B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
hum13b8
antibodies
solution
sequence
Prior art date
Application number
EA201591133A
Other languages
English (en)
Russian (ru)
Other versions
EA201591133A1 (ru
Inventor
Рамеш С. Каши
Аникет Бадкар
Original Assignee
Мэрк Шарп Энд Доме Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA034616(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мэрк Шарп Энд Доме Корп. filed Critical Мэрк Шарп Энд Доме Корп.
Publication of EA201591133A1 publication Critical patent/EA201591133A1/ru
Publication of EA034616B1 publication Critical patent/EA034616B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201591133A 2012-12-13 2013-12-09 СТАБИЛЬНЫЙ СОСТАВ В ВИДЕ РАСТВОРА АНТИТЕЛА HUM13B8-b К IL-23p19 И СПОСОБ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ, ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ ИЛИ ПРОЛИФЕРАТИВНОГО НАРУШЕНИЯ EA034616B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13
PCT/US2013/073825 WO2014093203A1 (en) 2012-12-13 2013-12-09 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES

Publications (2)

Publication Number Publication Date
EA201591133A1 EA201591133A1 (ru) 2015-10-30
EA034616B1 true EA034616B1 (ru) 2020-02-27

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591133A EA034616B1 (ru) 2012-12-13 2013-12-09 СТАБИЛЬНЫЙ СОСТАВ В ВИДЕ РАСТВОРА АНТИТЕЛА HUM13B8-b К IL-23p19 И СПОСОБ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ, ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ ИЛИ ПРОЛИФЕРАТИВНОГО НАРУШЕНИЯ

Country Status (31)

Country Link
US (3) US12509509B2 (show.php)
EP (1) EP2931313B1 (show.php)
JP (1) JP6266012B2 (show.php)
KR (1) KR102004585B1 (show.php)
CN (1) CN104870016B (show.php)
AU (1) AU2013359767B2 (show.php)
BR (1) BR112015013540B1 (show.php)
CA (1) CA2894869C (show.php)
CL (1) CL2015001608A1 (show.php)
CY (1) CY1121895T1 (show.php)
DK (1) DK2931313T3 (show.php)
EA (1) EA034616B1 (show.php)
ES (1) ES2732861T3 (show.php)
HR (1) HRP20191137T1 (show.php)
HU (1) HUE045668T2 (show.php)
IL (3) IL278295B2 (show.php)
LT (1) LT2931313T (show.php)
MX (1) MX357936B (show.php)
MY (1) MY187921A (show.php)
NZ (1) NZ708443A (show.php)
PE (1) PE20151524A1 (show.php)
PH (1) PH12015501296A1 (show.php)
PL (1) PL2931313T3 (show.php)
PT (1) PT2931313T (show.php)
RS (1) RS59057B1 (show.php)
SI (1) SI2931313T1 (show.php)
SM (1) SMT201900414T1 (show.php)
TR (1) TR201909584T4 (show.php)
UA (1) UA117466C2 (show.php)
WO (1) WO2014093203A1 (show.php)
ZA (1) ZA201504408B (show.php)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20200093927A1 (en) * 2017-03-31 2020-03-26 Meiji Seika Pharma Co., Ltd. Aqueous formulation and in-syringe aqueous formulation, and antibody protein deaggregation agent and antibody protein deaggregation method
EP3762015B1 (en) * 2018-03-05 2025-12-24 Janssen Biotech, Inc. Guselkumab for use in the treatment of crohn's disease with a dosage regimen
SG11202104166QA (en) * 2018-11-21 2021-05-28 Regeneron Pharma High concentration protein formulation
US12098195B2 (en) 2018-11-27 2024-09-24 Innovent Biologics (Suzhou) Co., Ltd. Anti-IL-23p19 antibody and use thereof in treating diseases
UA128098C2 (uk) 2019-02-18 2024-04-03 Елі Ліллі Енд Компані Водна фармацевтична композиція антитіла проти il-17a
EP3928101B1 (en) 2019-02-20 2024-10-09 Amgen Inc. Methods of determining protein stability
CN113825768A (zh) * 2019-04-15 2021-12-21 太阳药业有限公司 用于治疗患有银屑病关节炎的受试者的方法
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
TW202535466A (zh) * 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CN115135671B (zh) * 2019-12-20 2026-01-02 新石生物制药有限公司 抗白介素-23 p19的抗体及其使用方法
US20230173069A1 (en) * 2020-05-13 2023-06-08 Innovent Biologics (Suzhou) Co., Ltd. Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
WO2025071362A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-23 항체의 안정한 액상 제형

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311253A1 (en) * 2008-06-03 2009-12-17 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20110229490A1 (en) * 2008-08-27 2011-09-22 Schering Corporation Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401820A (en) 1981-01-23 1983-08-30 Tanabe Seiyaku Co., Ltd. Process for racemizing optically active α-amino acids or a salt thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1989009402A1 (fr) 1988-03-30 1989-10-05 Toray Industries, Inc. PREPARATION LYOPHILISEE CONTENANT UN ANTICORPS DE L'INTERFERON beta ANTIHUMAIN MARQUE PAR UNE ENZYME ET KIT D'ANALYSE ENZYMATIQUE CONTENANT CETTE PREPARATION
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
US5762905A (en) 1992-09-16 1998-06-09 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE194291T1 (de) 1995-09-18 2000-07-15 Intracel Corp Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DE69942671D1 (de) 1998-12-01 2010-09-23 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
EP1154796B1 (en) 1999-02-22 2007-06-20 University of Connecticut Novel albumin-free factor viii formulations
AR022890A1 (es) 1999-03-11 2002-09-04 Schering Corp Citoquinas mamiferas; reactivos relacionados y metodos
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
AU780163B2 (en) 1999-09-09 2005-03-03 Merck Sharp & Dohme Corp. Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
EP1233790A2 (en) 1999-10-22 2002-08-28 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products in cancer therapy
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
EP1801123A3 (en) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2002072636A2 (en) 2000-12-28 2002-09-19 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP1492554B1 (en) 2001-06-21 2019-08-21 Althea Technologies, Inc. Spherical protein particles
BRPI0210579B8 (pt) 2001-06-26 2021-05-25 Amgen Fremont Inc anticorpo e composição farmacêutica
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
WO2003039485A2 (en) 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
AU2003219958B2 (en) 2002-02-27 2006-01-05 Immunex Corporation Polypeptide formulation
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003265361A1 (en) 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
PT3417875T (pt) 2003-02-10 2020-08-24 Biogen Ma Inc Formulação de imunoglobulinas e método de preparação das mesmas
PT1601694E (pt) 2003-03-10 2009-12-03 Schering Corp Utilizações de agonistas e antagonistas de il-23; reagentes relacionados
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
NZ543498A (en) 2003-05-14 2007-06-29 Immunogen Inc A conjugate comprising an antibody chemically coupled to a maytansinoid
ATE518888T1 (de) 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005047324A2 (en) 2003-11-10 2005-05-26 Schering Corp Interleukin-10 antibodies
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
WO2005063291A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
CA2552750C (en) 2004-01-07 2021-11-09 Chiron Corporation M-csf-specific monoclonal antibody and uses thereof
CA2555791A1 (en) 2004-02-12 2005-08-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Highly concentrated liquid formulations of anti-egfr antibodies
CN1942201B (zh) 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
NZ549893A (en) 2004-03-24 2010-05-28 Facet Biotech Corp Use of anti-alpha5beta1 antibodiesin a stabilising solution to inhibit cancer cell proliferation
JP4879884B2 (ja) 2004-04-12 2012-02-22 メディミューン，エルエルシー 抗−ｉｌ−９抗体製剤及びその使用法
ATE476993T1 (de) 2004-06-07 2010-08-15 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
JP5042828B2 (ja) 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
AR062247A1 (es) 2005-03-08 2008-10-29 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti-ctla-4
CA2604840A1 (en) 2005-04-18 2006-10-26 Xtl Biopharmaceuticals Ltd. Stabilized anti-hepatitis b (hbv) antibody formulations
ATE505489T1 (de) 2005-04-22 2011-04-15 Lilly Co Eli Tgf-beta-1-spezifische antikörper
RU2406760C3 (ru) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN105153306B (zh) 2005-06-07 2020-12-11 艾斯巴技术-诺华有限责任公司 抑制TNFα的稳定和可溶的抗体
EP1896505A2 (en) 2005-06-15 2008-03-12 Schering Corporation Anti-igf1r antibody formulations
DK2452694T3 (en) 2005-06-30 2019-03-04 Janssen Biotech Inc Anti-IL-23 antibodies, compositions, methods and applications
MX2008001068A (es) 2005-07-29 2008-03-19 Amgen Inc Formulacion que inhibe la agregacion de proteina.
KR101566393B1 (ko) 2005-08-03 2015-11-05 이뮤노젠 아이엔씨 면역접합체 제형
EA013506B1 (ru) 2005-08-25 2010-06-30 Эли Лилли Энд Компани Антитело к il-23 и его применение
SG10201402712QA (en) 2005-08-31 2014-08-28 Merck Sharp & Dohme Engineered anti-il-23 antibodies
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
BRPI0616359B8 (pt) 2005-09-30 2022-08-30 Medimmune Ltd Composição farmacêutica, processo para purificação de um anticorpo de il-13 e uso de uma composição farmacêutica contendo um anticorpo
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
EP1998806A1 (en) 2006-03-28 2008-12-10 F. Hoffmann-Roche AG Anti-igf-1r human monoclonal antibody formulation
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
EP2019841A2 (en) 2006-04-21 2009-02-04 Novartis AG Antagonist anti-cd40 antibody pharmaceutical compositions
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
SG176427A1 (en) 2006-10-27 2011-12-29 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
AU2007328960B2 (en) 2006-12-05 2013-01-17 Crucell Holland B.V. Liquid anti-rabies antibody formulations
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
JP5577098B2 (ja) 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
EP2114451A2 (en) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
RS58098B1 (sr) * 2007-02-23 2019-02-28 Merck Sharp & Dohme Anti-il-23p19 antitela proizvedena genetičkim inženjerstvom
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
WO2008121615A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
TWI614028B (zh) 2007-06-14 2018-02-11 百健Ｍａ公司 抗體調配物
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
CA2692165A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US20100286038A1 (en) 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
US20090181027A1 (en) 2007-09-28 2009-07-16 Paul Dal Monte Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
CN101896163A (zh) 2007-12-21 2010-11-24 弗·哈夫曼-拉罗切有限公司 抗体制剂
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
UA100255C2 (uk) 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Фармацевтична композиція
US20110060290A1 (en) 2008-02-07 2011-03-10 Amgen Inc. Stabilized protein compositions
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
ES2640533T3 (es) 2008-04-09 2017-11-03 Genentech, Inc. Composiciones y métodos novedosos para el tratamiento de enfermedades relacionadas con la inmunidad
US8460886B2 (en) 2008-07-04 2013-06-11 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
US10188600B2 (en) 2008-09-19 2019-01-29 Pfizer Inc. Stable liquid antibody formulation
MX374128B (es) 2008-10-29 2025-03-05 Ablynx Nv Formulaciones de moléculas de unión a antígeno de dominio sencillo.
WO2010062372A2 (en) 2008-11-03 2010-06-03 President And Fellows Of Harvard College Methods for modulating nf-kb using gibberellins
CA2742990A1 (en) 2008-11-17 2010-05-20 Genentech, Inc. Method and formulation for reducing aggregation of a macromolecule under physiological conditions
MX2011005672A (es) * 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
RU2011140486A (ru) 2009-03-06 2013-04-20 МЕДИММЬЮН, ЭлЭлСи Композиции, содержащие гуманизированные антитела к cd19
RU2011140498A (ru) 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
EP2230312A1 (en) 2009-03-19 2010-09-22 Helmholtz-Zentrum für Infektionsforschung GmbH Probe compound for detecting and isolating enzymes and means and methods using the same
NZ595694A (en) 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US9155745B2 (en) 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
JP2012533548A (ja) 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011024862A1 (ja) 2009-08-31 2011-03-03 三洋化成工業株式会社 タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及び液体洗剤組成物、並びに、この安定化剤を用いるタンパク質の安定化方法
ES2788869T3 (es) 2009-09-03 2020-10-23 Merck Sharp & Dohme Anticuerpos anti-GITR
WO2011028962A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
EP2496707B1 (en) 2009-11-04 2020-02-26 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
TW201636048A (zh) 2009-12-21 2016-10-16 建南德克公司 抗體調配物
AU2010338305A1 (en) 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US8318807B2 (en) 2010-02-03 2012-11-27 Laurus Labs Private Limited Pterostilbene cocrystals
KR20130031247A (ko) 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자（ｎｇｆ） 항체 조성물
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
EP2590971A4 (en) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc COMPOUNDS SUITABLE FOR ANTIVIRAL ACTIVE SUBSTANCES, COMPOSITIONS AND METHOD OF USE THEREOF
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
AU2011312191B2 (en) 2010-10-06 2015-07-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
BR112013024493A2 (pt) 2011-03-25 2018-06-26 Amgen Inc. cristais de anticorpo antiesclerostina e formulações dos mesmos
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
JP2014510152A (ja) 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
EP2771319B1 (en) 2011-10-27 2022-03-02 Massachusetts Institute of Technology Amino acid derivatives functionalized on the n- terminal capable of forming drug incapsulating microspheres
SG11201403792TA (en) 2012-01-23 2014-10-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
EP3912639A1 (en) * 2012-03-07 2021-11-24 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2013285422B2 (en) 2012-07-04 2017-04-27 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014078627A1 (en) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins
EP2931311A4 (en) 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
SG11201506372RA (en) 2013-03-13 2015-09-29 Seattle Genetics Inc Cyclodextrin and antibody-drug conjugate formulations
ES2822665T3 (es) 2013-05-31 2021-05-04 Merck Sharp & Dohme Terapias de combinación para el cáncer
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
CA2927434C (en) 2013-10-16 2022-07-19 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
RU2589691C2 (ru) 2014-06-16 2016-07-10 Общество с ограниченной ответственностью "Промоген-МАТ" Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
MX2017000857A (es) 2014-07-18 2017-10-11 Advaxis Inc Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
SMT202200285T1 (it) 2014-08-11 2022-09-14 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
KR102321168B1 (ko) 2014-08-19 2021-11-02 머크 샤프 앤드 돔 코포레이션 항-tigit 항체
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
BR112017010198A2 (pt) 2014-11-17 2017-12-26 Genentech Inc terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
EP3237000A1 (en) 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
MX389267B (es) 2014-12-23 2025-03-20 Bristol Myers Squibb Co Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmumorreceptor (tigit).
JP2018502123A (ja) 2015-01-20 2018-01-25 イミューンエクサイト， インコーポレイテッド 癌免疫療法のための組成物及び方法
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
KR20250020678A (ko) 2015-03-04 2025-02-11 머크 샤프 앤드 돔 엘엘씨 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN108136001B (zh) 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
ES2813580T3 (es) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
US11326211B2 (en) 2015-04-17 2022-05-10 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to PD-1 antagonists
KR20250107941A (ko) 2015-04-28 2025-07-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
EP3892284B1 (en) 2015-05-29 2024-05-22 Merck Sharp & Dohme LLC Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EA201890456A1 (ru) 2015-08-07 2018-07-31 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
WO2017030823A2 (en) 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MX2018002586A (es) 2015-09-01 2020-11-24 First Wave Bio Inc Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala.
CN117510633A (zh) 2015-09-02 2024-02-06 伊缪泰普有限公司 抗lag-3抗体
WO2017048824A1 (en) 2015-09-14 2017-03-23 Compass Therapeutics Llc COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-β
US20170097333A1 (en) 2015-09-28 2017-04-06 Merck Sharp & Dohme Corp. Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
MX395336B (es) 2015-09-28 2025-03-25 Suzhou Suncadia Biopharmaceuticals Co Ltd Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
CN108368176B (zh) 2015-10-01 2022-06-07 波滕扎治疗公司 抗tigit抗原结合蛋白及其使用方法
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EP3394099A4 (en) 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations of Manipulated Anti- IL-10 Antibodies
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
IL262892B2 (en) 2016-05-18 2024-04-01 Boehringer Ingelheim Int Anti pd-1 and anti-lag3 antibodies for cancer treatment
KR102838691B1 (ko) 2016-06-14 2025-07-25 젠코어 인코포레이티드 이중특이적 체크포인트 억제제 항체
WO2018091729A2 (en) 2016-11-21 2018-05-24 Zaklady Farmaceutyczne Polpharma Sa Aqueous pharmaceutical formulations
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102624564B1 (ko) 2017-05-02 2024-01-12 머크 샤프 앤드 돔 엘엘씨 항-ctla4 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-ctla4 항체의 안정한 제제 및 그의 사용 방법
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
CA3061050A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN111107873A (zh) 2017-09-05 2020-05-05 默沙东公司 用于降低生物制剂粘度的化合物
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311253A1 (en) * 2008-06-03 2009-12-17 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20110229490A1 (en) * 2008-08-27 2011-09-22 Schering Corporation Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies

Also Published As

Publication number Publication date
TR201909584T4 (tr) 2019-07-22
PE20151524A1 (es) 2015-11-06
CN104870016A (zh) 2015-08-26
EP2931313B1 (en) 2019-05-08
PH12015501296B1 (en) 2015-08-24
PH12015501296A1 (en) 2015-08-24
WO2014093203A1 (en) 2014-06-19
HRP20191137T1 (hr) 2019-09-20
ES2732861T3 (es) 2019-11-26
CL2015001608A1 (es) 2015-10-30
IL307581A (en) 2023-12-01
EA201591133A1 (ru) 2015-10-30
MX357936B (es) 2018-07-31
SMT201900414T1 (it) 2019-09-09
SI2931313T1 (sl) 2019-09-30
HUE045668T2 (hu) 2020-01-28
NZ708443A (en) 2018-05-25
ZA201504408B (en) 2017-09-27
US12509509B2 (en) 2025-12-30
KR102004585B1 (ko) 2019-07-26
CN104870016B (zh) 2018-05-08
KR20150092763A (ko) 2015-08-13
MX2015007213A (es) 2016-08-03
EP2931313A1 (en) 2015-10-21
HK1215194A1 (en) 2016-08-19
BR112015013540A2 (pt) 2017-11-14
CY1121895T1 (el) 2020-10-14
RS59057B1 (sr) 2019-08-30
JP6266012B2 (ja) 2018-01-24
UA117466C2 (uk) 2018-08-10
CA2894869A1 (en) 2014-06-19
US20240239884A1 (en) 2024-07-18
JP2016505572A (ja) 2016-02-25
PL2931313T3 (pl) 2019-10-31
PT2931313T (pt) 2019-07-10
US20150329632A1 (en) 2015-11-19
MY187921A (en) 2021-10-28
CA2894869C (en) 2021-06-15
EP2931313A4 (en) 2016-08-03
IL239150A0 (en) 2015-07-30
AU2013359767A1 (en) 2015-07-23
LT2931313T (lt) 2019-09-25
AU2013359767B2 (en) 2018-04-05
IL278295B2 (en) 2024-03-01
IL278295A (show.php) 2020-12-31
US20210188964A1 (en) 2021-06-24
BR112015013540B1 (pt) 2021-04-27
IL239150B (en) 2020-11-30
DK2931313T3 (da) 2019-07-15
BR112015013540A8 (pt) 2018-04-17
IL278295B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US20240239884A1 (en) SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
JP5931442B2 (ja) 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤
US20180008707A1 (en) Stable liquid formulation for monoclonal antibodies
JP2020500195A (ja) アフリベルセプト製剤及びその使用
CN105051064A (zh) 抗TNF-α抗原结合蛋白
CA2949212A1 (en) Antibody formulation
US20230173069A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
CN113453719A (zh) 包含抗cd47抗体的制剂及其制备方法和用途
JP2021503472A (ja) 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
US20210253692A1 (en) High Concentration Liquid Antibody Formulations
WO2020259593A1 (zh) 包含抗lag-3抗体的制剂、其制备方法及其用途
HK1215194B (en) Solution formulations of engineered anti-il-23p19 antibodies
EP3808777A1 (en) Stable liquid antibody formulations
Elkordy¹ et al. Application of approved and marketed products of
WO2025153973A1 (en) Highly concentrated liquid formulations for antibodies
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor
HK40000750A (en) Antibody formulations